Skip to main content Skip to main navigation menu Skip to site footer

Treatment of infantile hemangioma: case report

  • Kartika Setiawaty ,
  • Nadirah Rasyid Ridha ,
  • Purnamasari Natsir ,
  • Muhammad Farid Huzein ,
  • Andi Dwi Bahagia Febriani ,

Abstract

Background: Although benign in origin, infantile hemangiomas can occasionally cause lifelong deformity, functional disability, and even life-threatening consequences. As a result, therapy is favored above an active observation plan. When treating infantile hemangiomas at high risk, the first line of therapy should be systemic propranolol. While oral propranolol is generally regarded as a safe and effective medication, it is important to consider potential adverse effects. Further research and evidence-based practices are needed to improve clinical results.

Case report: Here, we describe a 3-month-old child who had an infantile hemangioma and how oral propranolol significantly improved the lesion. The patient's mother takes her to the hospital when she notices a reddish mass that extends from her nasal bridge to her right cheek. After three days, the patient's red mass had lessened. The kid was monitored in the clinic for three hours following the initial increase in propranolol dosage, which was raised to 2 mg/kg/day. Every week, the patient was monitored at the clinic. The child's weight had climbed to 7 kg after 4 weeks, and she had no side effects from an increased propranolol dosage.

Conclusion: A critical factor is the early diagnosis of at-risk infantile haemangiomas, which calls for pediatricians, general practitioners, and health visitors to be more alert in order to spot potentially troublesome infantile haemangiomas in the first two to three weeks of life.

References

  1. Léauté-Labrèze C, Harper JI, Hoeger PH. Infantile haemangioma. Lancet. 2017;390(10089):85–94. Available from: http://dx.doi.org/10.1016/s0140-6736(16)00645-0
  2. Darrow DH, Greene AK, Mancini AJ, Nopper AJ. Diagnosis and Management of Infantile Hemangioma: Executive Summary. Pediatrics. 2015;136(4):786–91. Available from: http://dx.doi.org/10.1542/peds.2015-2482
  3. Luu M, Frieden IJ. Infantile hemangiomas and structural anomalies: PHACE and LUMBAR syndrome. Semin Cutan Med Surg. 2016;35(3):117–23. Available from: http://dx.doi.org/10.12788/j.sder.2016.047
  4. Antaya RJ. Infantile Hemangioma [Internet]. Medscape. Universidade do Estado do Mato Grosso - UNEMAT; 2023. Available from: https://emedicine.medscape.com/article/1083849-overview
  5. Tan X, Guo S, Wang C. Propranolol in the Treatment of Infantile Hemangiomas. Clin Cosmet Investig Dermatol. 2021;14:1155–63. Available from: https://pubmed.ncbi.nlm.nih.gov/34511960
  6. Eichenfield LF, Frieden IJ, Mathes E, Zaenglein A. Neonatal and Infant Dermatology. Pediatric Dermatology. Elsevier Health Sciences; 2014. 752 p.
  7. Bolognia JL, Schaffer J V., Lorenzo Cerroni. Dermatology: 2-Volume Set. Fourth. Pediatric Dermatology. Elsevier; 2017. 289 p.
  8. Krowchuk DP, Frieden IJ, Mancini AJ, Darrow DH, Blei F, Greene AK, et al. Clinical Practice Guideline for the Management of Infantile Hemangiomas. Pediatrics. 2019;143(1). Available from: http://dx.doi.org/10.1542/peds.2018-3475
  9. Tiemann L, Hein S. Infantile Hemangioma: A Review of Current Pharmacotherapy Treatment and Practice Pearls. J Pediatr Pharmacol Ther. 2020;25(7):586–99. Available from: https://pubmed.ncbi.nlm.nih.gov/33041713
  10. Borkar N, Sharma A, Hota D. Complicated Infantile Hemangioma Successfully Treated with Topical Timolol 0.5% Solution: A Case Report. J Cutan Aesthet Surg. 2021;14(4):440–2. Available from: https://pubmed.ncbi.nlm.nih.gov/35283589
  11. Macca L, Altavilla D, Di Bartolomeo L, Irrera N, Borgia F, Li Pomi F, et al. Update on Treatment of Infantile Hemangiomas: What’s New in the Last Five Years? Front Pharmacol. 2022;13:879602. Available from: https://pubmed.ncbi.nlm.nih.gov/35721150
  12. Kompyang Rahayu N, Emily A. Clinical profile of steroid-induced glaucoma in Bali Mandara Eye Hospital year 2019. Intisari Sains Medis. 2021;12(1):6–8. Available from: https://mail2.isainsmedis.id/index.php/ism/article/view/872
  13. Subandiyah K, Khanifa H, Kardani AK. Effect of corticosteroid and vitamin D3 as combined therapy on 25 (OH) vitamin D serum level and regulatory T (TReg) cells population in children with idiopathic nephrotic syndrome. Bali Med J. 2018;7(3):639–44.
  14. Aly MMD, Hamza AF, Abdel Kader HM, Saafan HA, Ghazy MS, Ragab IA. Therapeutic superiority of combined propranolol with short steroids course over propranolol monotherapy in infantile hemangioma. Eur J Pediatr. 2015;174(11):1503–9. Available from: http://dx.doi.org/10.1007/s00431-015-2561-1
  15. Fei Q, Lin Y, Chen X. Treatments for infantile Hemangioma: A systematic review and network meta-analysis. EClinicalMedicine. 2020;26:100506. Available from: https://pubmed.ncbi.nlm.nih.gov/33089121
  16. Chamli A, Aggarwal P, Jamil RT, Litaiem N. Hemangioma [Internet]. StatPearls. 2023. Available from: https://www.ncbi.nlm.nih.gov/books/NBK538232/
  17. Cai Y, Ge Y, Ung COL, Li F, Wang J, Xia C, et al. Treatment patterns and outcomes in children with infantile hemangiomas: A retrospective observational analysis. SAGE open Med. 2021;9:20503121211056844–20503121211056844. Available from: https://pubmed.ncbi.nlm.nih.gov/34938569
  18. Rotter A, de Oliveira ZNP. Infantile hemangioma: pathogenesis and mechanisms of action of propranolol. JDDG J der Dtsch Dermatologischen Gesellschaft. 2017;15(12):1185–90. Available from: http://dx.doi.org/10.1111/ddg.13365
  19. Babiak-Choroszczak L, Giżewska-Kacprzak K, Dawid G, Gawrych E, Bagłaj M. Safety assessment during initiation andmaintenance of propranolol therapy for infantile hemangiomas. Adv Clin Exp Med. 2019;28(3):375–84. Available from: http://dx.doi.org/10.17219/acem/94136
  20. Kowalska M, Dębek W, Matuszczak E. Infantile Hemangiomas: An Update on Pathogenesis and Treatment. J Clin Med. 2021;10(20):4631. Available from: https://pubmed.ncbi.nlm.nih.gov/34682753
  21. Kreshanti P, Putri NT, Martin VJ, Sukasah CL. The effectiveness of oral propranolol for infantile hemangioma on the head and neck region: A case series. Int J Surg Case Rep. 2021/06/19. 2021;84:106120. Available from: https://pubmed.ncbi.nlm.nih.gov/34216913
  22. Kagami S, Kaneko M, Kishi A, Katori T. Prolonged growth of infantile hemangioma after pulsed dye laser and oral propranolol treatment. J Dermatol. 2018;45(9):1109–12. Available from: http://dx.doi.org/10.1111/1346-8138.14517
  23. Chang L, Gu Y, Yu Z, Ying H, Qiu Y, Ma G, et al. When to stop propranolol for infantile hemangioma. Sci Rep. 2017;7:43292. Available from: https://pubmed.ncbi.nlm.nih.gov/28225076

How to Cite

Setiawaty, K., Ridha, N. R. ., Natsir, P. ., Huzein, M. F. ., & Febriani, A. D. B. . (2023). Treatment of infantile hemangioma: case report. Intisari Sains Medis, 15(1), 1386–1392. https://doi.org/10.15562/ism.v15i1.1853

HTML
0

Total
0

Share

Search Panel

Kartika Setiawaty
Google Scholar
Pubmed
ISM Journal


Nadirah Rasyid Ridha
Google Scholar
Pubmed
ISM Journal


Purnamasari Natsir
Google Scholar
Pubmed
ISM Journal


Muhammad Farid Huzein
Google Scholar
Pubmed
ISM Journal


Andi Dwi Bahagia Febriani
Google Scholar
Pubmed
ISM Journal